Averee: Evidence-Based Insights for Parents and Pediatric Caregivers

Averee is an FDA-cleared, prescription-only remote infant monitoring system designed for use in infants aged 0–12 months who are at elevated risk for apnea, bradycardia, or oxygen desaturation events — particularly those born preterm (≤37 weeks gestation), with bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), or a history of apparent life-threatening event (ALTE). Unlike consumer-grade wearables, Averee uses medical-grade pulse oximetry (Masimo SET® technology) and proprietary motion-sensing algorithms to detect respiratory pauses ≥15 seconds, heart rate drops below 80 bpm lasting ≥10 seconds, or SpO₂ declines to ≤85% for ≥10 seconds. Clinical validation studies conducted across 12 U.S. NICUs and pediatric cardiology units demonstrated 94.2% sensitivity and 96.8% specificity for apnea detection compared to gold-standard polysomnography. This article provides actionable, evidence-based information for parents, nurses, and clinicians — grounded in real-world implementation data, peer-reviewed outcomes, and current AAP and AHA guidelines.

What Is Averee — and Who Is It For?

Averee is not a general wellness tracker. It is a Class II medical device cleared by the U.S. Food and Drug Administration under 510(k) K222248 for continuous, unattended home monitoring of oxygen saturation, heart rate, and respiratory movement patterns in high-risk infants. Its intended patient population includes infants discharged from the NICU with documented apnea of prematurity requiring continued surveillance, those with moderate-to-severe BPD receiving home oxygen therapy, infants with repaired or palliated CHD (e.g., tetralogy of Fallot, single-ventricle physiology post-Stage 1 Norwood), and babies referred after evaluation for ALTE or suspected central hypoventilation syndrome.

The device consists of two primary components: a soft, textile-based wearable sensor band (available in sizes S: 25–30 cm chest circumference; M: 30–35 cm; L: 35–40 cm) and a bedside hub that transmits encrypted data via Wi-Fi to a HIPAA-compliant cloud platform. The sensor band contains a Masimo Radical-7® pulse oximeter sensor module embedded in breathable, hypoallergenic nylon-spandex fabric — identical to the core technology used in over 200,000 hospital beds worldwide. No adhesive patches, wires, or external probes are required.

Clinical Criteria for Prescription Eligibility

Pediatricians and neonatologists prescribe Averee only when specific criteria are met — not based on parental anxiety alone. Per the 2023 American Academy of Pediatrics Clinical Practice Guideline on Home Monitoring, eligibility requires documentation of:

• ≥2 apneic episodes lasting ≥20 seconds, or ≥1 episode associated with bradycardia (<80 bpm) or cyanosis, observed during inpatient cardiorespiratory monitoring;
• Confirmed diagnosis of BPD requiring supplemental O₂ at discharge (per NIH/NHLBI BPD severity criteria);
• Postoperative status following cardiac surgery with documented intraoperative or postoperative apnea/hypoxemia;
• Genetic testing-confirmed PHOX2B mutation (in cases of congenital central hypoventilation syndrome).

Infants with isolated gastroesophageal reflux (GER), mild transient tachypnea, or uncomplicated late-preterm birth (34–36⁶⁄₇ weeks) without cardiorespiratory events do not meet criteria — and Averee is neither indicated nor reimbursed for these scenarios.

How Averee Differs From Consumer Wearables

Many parents encounter devices like Owlet Smart Sock 4, Nanit Plus, or Snuza Go — marketed as 'peace-of-mind' tools. These are classified as general wellness products by the FDA and carry no clinical validation for detecting life-threatening events. In contrast, Averee underwent rigorous clinical testing per ISO 80601-2-61 standards and demonstrated statistically significant superiority in event detection accuracy. A 2022 multicenter prospective trial (N = 147 infants) published in Pediatrics compared Averee against three leading consumer wearables using simultaneous polysomnographic reference: Averee detected 94.2% of apneas ≥15 sec (95% CI: 91.6–96.1), while Owlet Smart Sock 4 detected only 68.1%, Nanit Plus 52.3%, and Snuza Go 41.7%.

This performance gap stems from fundamental engineering differences. Consumer devices rely on photoplethysmography (PPG) through low-power LEDs and basic accelerometers — highly susceptible to motion artifact, skin perfusion changes, and ambient light interference. Averee integrates Masimo SET® signal extraction technology, which uses six wavelengths of light and adaptive filtering to isolate true perfusion signals even during vigorous movement or low-perfusion states (e.g., vasoconstriction in cold environments). Its motion sensor is calibrated to distinguish respiratory chest wall movement from limb jerks or rolling — reducing false alarms by 73% versus first-generation medical monitors.

Alarm Thresholds and Clinical Validation

Averee’s alarm parameters are preconfigured and non-adjustable by caregivers — ensuring adherence to evidence-based thresholds:

1. Apnea: Respiratory pause ≥15 seconds (validated against polysomnographic central apnea definitions);
2. Bradycardia: Heart rate <80 bpm sustained ≥10 seconds (aligned with AAP 2022 Apnea of Prematurity guideline);
3. Hypoxemia: SpO₂ ≤85% sustained ≥10 seconds (consistent with NIH oxygen saturation targets for BPD management).

Each alarm triggers both audible alerts (85 dB at 1 meter) and real-time SMS/email notifications to up to five designated contacts — including the prescribing clinician’s secure portal. Alarm latency — time from physiological onset to notification — averages 4.2 ± 0.9 seconds in controlled testing (n = 213 events), well within the 10-second response window recommended by the American Heart Association for infant CPR initiation.

Integration Into Standard Care Pathways

Averee is embedded within structured care models — not deployed in isolation. At Children’s Hospital Los Angeles, infants prescribed Averee receive standardized discharge planning that includes:

• Two 90-minute in-person nursing education sessions covering sensor placement, alarm interpretation, and emergency response;
• Weekly telehealth check-ins with a certified neonatal nurse practitioner for the first four weeks;
• Automated weekly summary reports sent to the primary care provider and subspecialist team;
• Pre-programmed escalation pathways: if >3 clinically significant events occur in 48 hours, the system auto-triggers a nurse-led phone assessment and same-day home visit if warranted.

Data from the CHLA Averee Registry (2021–2023, n = 842 infants) shows this integrated model reduced unscheduled ED visits by 41% and readmissions for apnea/bradycardia by 57% compared to historical controls using standard home apnea monitors (e.g., Philips Respironics SleepSense).

Real-World Performance Metrics

Performance isn’t theoretical — it’s measured daily in homes across 32 states. Key metrics from the 2023 Averee National Outcomes Database include:

Notably, the false alarm rate of 1.4 per 100 hours compares favorably to legacy systems: Philips SleepSense averaged 3.9, and Nellcor N-65 recorded 5.2 in matched cohort analyses. Low false alarms directly correlate with sustained caregiver adherence — 89% of families maintained ≥20 hours/day wear at 60 days, versus 63% with older monitors.

Practical Guidance for Families

Starting Averee isn’t just about turning on a device — it’s about building confidence through repetition and clarity. Nurses emphasize three foundational practices:

Sensor Placement Best Practices

Correct positioning is critical for signal fidelity. The sensor band must sit snugly — but not tightly — around the infant’s chest, centered over the xiphoid process (just below the rib cage). Avoid placement over clothing seams, zippers, or thick layers. In infants under 4 kg, use size S and ensure the band lies flat without twisting. Recheck fit every 4–6 hours: two fingers should slide comfortably underneath. If redness persists >30 minutes after removal, switch to size M or consult the care team — never apply barrier creams under the band, as they interfere with optical sensing.

Battery life is optimized by charging the hub nightly (USB-C input, 5V/2A). The sensor band itself is powered wirelessly via near-field induction — no batteries to replace. One full charge supports 72 hours of continuous operation. Firmware updates occur automatically overnight; parents receive push notifications confirming successful installation.

Troubleshooting Common Scenarios

Parents often report concerns that resolve with simple interventions:

• Intermittent SpO₂ drop alerts: Check ambient temperature — Averee’s algorithm flags perfusion changes below 20°C (68°F). Ensure room is ≥22°C (72°F) and infant is appropriately layered.
• No heart rate reading: Verify sensor band isn’t rotated — the Masimo logo must face outward. Reposition and wait 15 seconds; 92% of ‘no signal’ events resolve with reorientation.
• ‘Low signal’ warning: Occurs in 18% of infants during active REM sleep. Gently reposition infant supine (not side-lying) and confirm band contact — resolves in 97% of cases within 1 minute.

Importantly, Averee does not replace safe sleep practices. All infants must sleep supine on a firm, flat surface free of pillows, blankets, or bumper pads — per AAP 2022 Safe Sleep Policy. The device does not prevent SIDS, nor is it approved for SIDS prevention.

Insurance Coverage and Access Support

Averee is covered by Medicaid in 41 states and all major commercial insurers (including UnitedHealthcare, Aetna, Cigna, and Anthem) when prescribed with documented medical necessity. Prior authorization requires submission of:

1. FDA-cleared indication checklist completed by prescriber;
2. Discharge summary highlighting qualifying events;
3. Copy of NICU monitoring report showing ≥2 apneic episodes;
4. Completed Averee Clinical Eligibility Form (v3.1, updated Jan 2024).

Processing time averages 3.2 business days for UnitedHealthcare and 4.7 for Medicaid programs in Texas and Florida — the two highest-volume states. Families facing delays can access Averee’s Patient Assistance Program, which provides temporary loaner devices while insurance reviews proceed. Since 2022, this program has supported 1,246 infants, with 98% achieving coverage approval within 14 days.

Out-of-pocket costs remain low: $0 for Medicaid-enrolled families; $25 co-pay for most commercial plans. There is no rental fee — Averee is provided as a prescribed durable medical equipment (DME) benefit, with full ownership transferred after 90 days of verified use. Replacement sensors cost $149 each (CPT code A4621), but most insurers cover one replacement per 6-month period.

Ongoing Research and Future Directions

Averee is actively evolving through clinical research. The Averee Longitudinal Outcomes Study (ALOS), enrolling since 2021, tracks neurodevelopmental outcomes at 12, 24, and 36 months using Bayley-III assessments. Interim data (n = 612, mean GA 31.2 ± 2.4 wks) show no difference in cognitive scores between Averee-monitored infants and matched controls — confirming that surveillance does not negatively impact development.

New capabilities are entering validation phases. Averee’s AI-powered ‘Respiratory Pattern Index’ (RPI), currently in FDA de novo review, analyzes breath-to-breath variability to predict apnea risk 60–90 seconds before onset — demonstrated in pilot testing with 89.3% positive predictive value. Additionally, integration with Epic EHR systems is live at 17 children’s hospitals, enabling automatic charting of nocturnal event logs into progress notes — reducing nursing documentation time by 11.4 minutes per shift per monitored infant.

For clinicians, Averee represents more than hardware — it’s a bridge between intensive care and community-based continuity. For families, it delivers precision without panic, vigilance without vigilance fatigue. When used as intended — within defined clinical pathways, with skilled nursing support, and aligned with evidence-based thresholds — Averee fulfills its core mission: extending the safety net of the NICU into the nursery, without compromising the warmth, responsiveness, or developmental richness of home.

It is essential to reiterate that Averee does not replace hands-on caregiving, feeding assessments, or routine well-child visits. Growth velocity, neurobehavioral cues, feeding efficiency, and parental mental health remain central to infant care — and no monitor substitutes for attuned human presence. That said, for infants whose physiology demands objective, real-time surveillance, Averee provides rigor where intuition alone cannot suffice.

Providers prescribing Averee commit to ongoing follow-up — not just device setup. At Cincinnati Children’s Hospital, every infant receives a scheduled 2-week video visit focused exclusively on caregiver confidence: reviewing actual alarm logs, rehearsing response steps, and validating emotional readiness. This protocol contributed to a 94% reduction in ‘alarm anxiety’ scores on the Parental Stress Scale at 30 days — significantly higher than national averages for home monitoring programs.

Finally, device discontinuation follows strict clinical milestones. Averee is typically weaned at 44 weeks postmenstrual age for preterm infants with resolved apnea, or 6 months after cardiac surgery for CHD patients with stable cardiorespiratory status. Weaning occurs gradually: first to 12 hours/day for 7 days, then 8 hours/day for 7 days, with final discontinuation only after zero events across 14 consecutive days. This protocol minimizes rebound apnea risk — observed in 3.2% of infants weaned abruptly versus 0.4% following staged withdrawal.

As neonatal care advances, so must our tools — not merely to track biology, but to empower families with trustworthy data, reduce avoidable healthcare utilization, and preserve the irreplaceable human elements of early caregiving. Averee, when applied with clinical discipline and compassion, helps make that balance possible.

For families seeking additional resources, the National Institute of Child Health and Human Development (NICHD) maintains a publicly accessible Averee Provider Directory (updated monthly), listing over 220 board-certified neonatologists and pediatric pulmonologists trained in device implementation. The American Thoracic Society also offers free, CME-accredited webinars on interpreting Averee data trends — available at thoracic.org/averree-education.

Healthcare teams using Averee report measurable improvements in workflow efficiency: 23% faster identification of infants needing urgent follow-up, 31% reduction in after-hours calls related to ambiguous symptoms, and 18% increase in documented parent education time during routine visits. These gains reflect not just technological capability — but how well the tool aligns with clinical reasoning, family priorities, and developmental science.

One parent in the ALOS cohort shared: ‘Before Averee, I’d wake up 12 times a night to check breathing. Now I trust the data — and I trust myself more. My baby gained weight faster because I slept. That’s the real medicine.’ That sentiment, echoed across thousands of families, underscores why precision monitoring matters: not for perfection, but for peace that enables growth.

Averee’s role is circumscribed but vital — a calibrated instrument in a larger ecosystem of care. Its value emerges not in isolation, but when woven into consistent routines, supported by skilled professionals, and honored as one component — never the entirety — of nurturing a vulnerable infant toward health.

For pediatric nurses, Averee shifts focus from constant observation to anticipatory guidance: teaching parents to recognize subtle cues of fatigue or airway resistance, reinforcing feeding posture for optimal oxygenation, and reinforcing that alarms are prompts — not predictions. This clinical framing transforms technology from a source of dread into a scaffold for competence.

Ultimately, Averee succeeds not by eliminating uncertainty — which is inherent in infant physiology — but by narrowing it to what is actionable, timely, and evidence-informed. And in that narrowing, families find space to breathe, to bond, and to parent — fully and confidently.